Supplementary Table 2: SARS-CoV-2 exposure

|  |  |
| --- | --- |
|  | Count (%) |
| PCR positive | 10/ 68 (14.7) |
| Antibody positive | Any serology positive | 62 (91.2) |
| Total IG to Nucleocapsid\* | 28/34 (82.4) |
| IgG to Nucleocapsid | 20/22 (90.9) |
| IgG to Spike | 37/39 (94.9) |
| IgA to Spike | 24/25 (96.0) |
| SARS-CoV-2 contact | Confirmed | 14 (23.0) |
| Suspected | 11 (18.0) |
| None | 36 (59.0) |

\* 22 from TBH only received antibody tests at their follow-up appointment (after 13 October 2020 when serology tests became available).

IgG- Immune globulin G

IgA- Immune globulin A